Postmarketing surveillance of new food ingredients: design and implementation of the program for the fat replacer olestra.
Following U.S. Food and Drug Administration (FDA) approval for the use of olestra, a noncaloric fat substitute (brand name Olean) in food snacks, the manufacturer agreed to provide safety updates on market experience to the FDA. However, guidelines for food product postmarketing surveillance (PMS) are not available and those typically used with medical products were only partly applicable. In modeling the Olean program, we drew from experience with consumer products and incorporated elements typical of medical product PMS. A cooperative effort was established with Olean snack manufacturers and a two-tiered, multidisciplinary approach enlisting Consumer Relations and Medical Affairs personnel was used to maximize use of specialized skills. The result of this effort was implementation of a reliable PMS system which could handle a high volume of reports from consumers while providing pertinent data required for medical interpretation of these reports. Summaries of data for the Olean snack manufacturers and FDA were generated in timely fashion. In addition to collection of the spontaneous reports from consumers, a clinical studies program was undertaken and an independent medical advisory panel was established. Through these, we gained perspective on the spontaneous reports and additional confirmation of the safety of olestra in savory snacks.
Slough
C L
CL
Department of Medical Affairs, Olean, Procter & Gamble Company, Cincinnati, OH 45224, USA.
Miday
R K
RK
Zorich
N L
NL
Jones
J K
JK
D002986:Clinical Trials as Topic; D003256:Community Participation; D003625:Data Collection; D003657:Decision Making; D019358:Fat Substitutes / Q000009:adverse effects*; D005227:Fatty Acids / Q000009:adverse effects*; D005503:Food Additives / Q000009:adverse effects*; D019649:Food Industry; D006801:Humans; D007373:Interinstitutional Relations; D011358:Product Surveillance, Postmarketing; D011634:Public Health; D011786:Quality Control; D013395:Sucrose / Q000009:adverse effects* / Q000031:analogs & derivatives; D014481:United States; D014486:United States Food and Drug Administration
D019358:Fat Substitutes; D005227:Fatty Acids; D005503:Food Additives; D013395:Sucrose; C013692:sucrose polyester